Sriarth Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-01-2025
- Paid Up Capital ₹ 0.10 M
as on 16-01-2025
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 16-01-2025
- Revenue -100.00%
(FY 2023)
- Profit -433.77%
(FY 2023)
- Ebitda -155.47%
(FY 2023)
- Net Worth -74.88%
(FY 2023)
- Total Assets -49.87%
(FY 2023)
About Sriarth Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Sri Singh and Raman Kaur serve as directors at the Company.
- CIN/LLPIN
U85191UP2015PTC068983
- Company No.
068983
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sriarth Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sri Singh  | Director | 18-Feb-2015 | Current |
| Raman Kaur | Additional Director | 20-Sep-2019 | Current |
Financial Performance of Sriarth Lifesciences.
Sriarth Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial fall in profitability, with a 433.77% decrease in profit. The company's net worth observed a substantial decline by a decrease of 74.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sriarth Lifesciences?
In 2023, Sriarth Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sripharma Lifesciences Private LimitedActive 1 year 26 days
Sri Singh and Raman Kaur are mutual person
- Singh Modular Hospital Infra Private LimitedActive 6 months 12 days
Sri Singh and Raman Kaur are mutual person
- Medi Equip Services Private LimitedActive 8 years 1 month
Sri Singh and Raman Kaur are mutual person
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Union Bank Of India : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jul 2015 | Union Bank Of India | ₹2.00 M | Open |
How Many Employees Work at Sriarth Lifesciences?
Unlock and access historical data on people associated with Sriarth Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sriarth Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sriarth Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
